SCHEMBL715629

SCHEMBL715629

CC(NC(=O)O)c1cc2cccc(Cl)c2nc1N1CCNC1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGAV P06756 1/20 0.39
ITGA5 P08648 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB5 P18084 1/20 0.39
ITGB8 P26012 1/20 0.39
IDH1 O75874 1/20 0.37
MAP3K5 Q99683 1/20 0.35
PIK3CD O00329 7/20 0.35
PIK3R2 O00459 4/20 0.35
PIK3CG P48736 4/20 0.35
PIK3R1 P27986 2/20 0.35
GPR139 Q6DWJ6 2/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
PDE2A O00408 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
XPO1 O14980 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8072 0.85 SOS1 (0.36) PIK3CDPIK3R2PIK3CGPIK3R1GPR139
SCHEMBL17530837 0.85 ADRA2A (0.34) PIK3CDPIK3CGPIK3R1GPR139
SCHEMBL714585 0.83 CYP1A2 (0.38) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL714586 0.83 CYP1A2 (0.38) ITGB3ITGB1ITGAVITGA5ITGA4
SCHEMBL716164 0.82 AKT1 (0.40) PIK3CDCYP3A4CYP2C9L3MBTL1
SCHEMBL717045 0.80 PIK3CB (0.40) PIK3CDPIK3CGCYP3A4CYP2C9
SCHEMBL716690 0.79 IDH1 (0.45) IDH1PIK3CDPIK3R2
SCHEMBL713901 0.79 AKT1 (0.43) GPR139CYP3A4CYP2C9L3MBTL1
SCHEMBL715607 0.79 CNR2 (0.43) PIK3CD
SCHEMBL714176 0.78 P2RX7 (0.38) PIK3CDPIK3CGPIK3R1GPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed
EP-2403847-A1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2012-01-11 EP disclosed
WO-2010100405-A1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 ITGB3 3535/4885ITGB1 4239/4885ITGAV 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.